Factory 99% Tizanidine HCl Powder CAS 51322-75-9 Chemical Intermediate Tizanidine HCl

• Customization: Available
• Powder: Yes
• Customized: Customized
• Model NO.: A945
• Certification: GMP, HSE, ISO 9001, USP, BP
• Suitable for: Elderly, Children, Adult
• State: Powder
• Purity: >99%
• Name: Tizanidine HCl
• CAS: 51322-75-9
• Appearance: White Powder
• Assay: 99%
• OEM: Available
• Sample: Available
• Suitable: Adult
• MOQ: 1g
• Function: Chemical Intermediate
• Transport Package: Foil Bag
• Specification: 99
• Trademark: /
• Origin: China
• Production Capacity: 10000 Kgs Per Month

Product Description

 

Product Name	Tizanidine HCl
Appearance	White Powder
CAS NO.	51322-75-9
Storage	Keep in a cool, dry, dark location

 

Tizanidine HCl, also known as DS 103-282, is an α2-adrenergic receptor agonist with the CAS number 64461-82-1. It has a molecular formula of C9H9Cl2N5S and a molecular weight of 290.1723 g/mol. This compound belongs to the class of organic compounds known as benzothiadiazoles.

 

1. Medical Therapy: Tizanidine HCl is primarily used in the management of spasticity resulting from various neurological conditions such as multiple sclerosis, spinal cord injury, and cerebral palsy.
2. Muscle Relaxation: It acts as a muscle relaxant, helping to alleviate muscle spasms and tightness.
3. Research Purposes: In scientific research, Tizanidine HCl is used to study the effects of α2-adrenergic receptor agonism on the central nervous system and neuromuscular function.

1. Inhibition of Neurotransmitter Release: Tizanidine HCl functions by inhibiting the release of neurotransmitters from central nervous system neurons, particularly those that are norepinephrine-containing.
2. α2-Adrenergic Receptor Agonism: By acting as an agonist at the α2-adrenergic receptors, it modulates the activity of the sympathetic nervous system, leading to muscle relaxation and reduction in spasticity.
3. Central Nervous System Modulation: Overall, Tizanidine HCl affects the central nervous system by altering neurotransmitter levels and receptor activity, which results in therapeutic benefits for patients with spasticity and related neuromuscular disorders.